Astrazeneca PLC (AZN) Receives ‘Analyst’ Rating

Astrazeneca PLC (AZN) : 2 brokerage houses believe that Astrazeneca PLC (AZN) is a Strong Buy at current levels. 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Astrazeneca PLC (AZN). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 4 Wall Street Analysts endorse the stock as a Buy with a rating of 2.

Astrazeneca PLC (AZN) : The highest level Astrazeneca PLC (AZN) is projected to reach is $41 for the short term and the lowest estimate is at $34. The consolidated price target from 3 rating analysts who initiate coverage on the stock is $36.79 and the possibility the share price can swing is $4.


Also, Equity Analysts at the Brokerage Firm, Argus Research, upgrades their rating on the shares of Astrazeneca PLC (NYSE:AZN). Argus Research has a Buy rating on the shares. Previously, the analysts had a Hold rating on the shares. As per the latest report, the brokerage house announces the price target to $38 per share. The rating by the firm was issued on August 29, 2016.

Astrazeneca PLC (NYSE:AZN): After opening at $33.19, the stock dipped to an intraday low of $33 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $33.8194 and the buying power remained strong till the end. The stock closed at $33.66 for the day, a gain of 1.69% for the day session. The total traded volume was 6,023,890. The stocks close on the previous trading day was $33.1.

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.